IP Library Granted Patent US 10,064,925
Granted Patent B2
US 10,064,925 · App. 14/786,898 · Granted Sep 4, 2018

Use of anti-CD47 agents to enhance immunization

Inventors: Diane Tseng (San Jose, CA); Jens-Peter Volkmer (Menlo Park, CA); Kipp Andrew Weiskopf (Menlo Park, CA); Stephen Willingham (Stanford, CA); Irving L. Weissman (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K39/0011C12N5/0645A61K2039/5154A61K2039/5158C12N2501/599C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,925
App. No.
14/786,898
Granted
Sep 4, 2018
Kind
B2
Abstract

Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.

Claims (10)

1. A method of inducing a CD8+ T cell immune response to a mammalian target cell, the method comprising:

(a) contacting in vitro

(i) a phagocytic antigen presenting cell (phAPC) population comprising one or both of mammalian macrophages and dendritic cells,

(ii) the mammalian target cell,

(iii) in the presence of an effective dose of an anti-CD47 agent that blocks the interaction between CD47 and SIRPα, selected from: an antibody that binds to CD47, an antibody that binds to SIRPα, a soluble SIRPα-binding CD47 fragment, and a soluble CD47-binding SIRPαfragment; to generate a loaded phAPC population; and

(b) contacting a CD8 + T cell population with the loaded phAPC population;

wherein the CD8 + T cell population generates a response specific to the mammalian target cell.

2. The method of claim 1 , wherein the CD8+ T cell population is selectively induced to respond to the mammalian target cell.

3. The method of claim 2 , wherein the CD8 + T cell population is a human T cell population.

4. The method of claim 1 , wherein the mammalian target cell is a human cancer cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 21, 2016
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039093/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2016
From: TSENG, DIANE; VOLKMER, JENS-PETER; WEISKOPF, KIPP ANDREW; WILLINGHAM, STEPHEN; WEISSMAN, IRVING L.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 038284/0081 →
Continuity (2)
Provisional Application 61817229 · Apr 29, 2013
Related Publication 20160144009A1 · May 26, 2016
Cited By (1)
US 12,404,340